Literature DB >> 26530486

PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma.

Shuanzeng Wei1, Virginia A LiVolsi2, Kathleen T Montone3, Jennifer J D Morrissette4, Zubair W Baloch5.   

Abstract

Oncocytic follicular carcinoma (OFC)/Hürthle cell carcinoma represents 3-4 % thyroid carcinomas and can be associated with more aggressive behavior and compromised survival compared to non-oncocytic thyroid carcinoma. In this study, we utilized targeted next-generation sequencing to investigate the molecular alterations in a heterogeneous group of clinically aggressive OFC. A total of 12 cases of OFC were included in this study. Targeted next-generation sequencing was performed using panels of 47 or 20 genes, which are frequently mutated in solid tumors. The case cohort comprised eight cases of angioinvasive OFC, two cases of poorly differentiated OFC, one case of OFC with anaplastic change, and one case of OFC with capsular invasion only. Five out of 12 cases (42 %) harbored TP53 mutation. PTEN mutations were also seen in three cases with TP53 mutation (25 %). Based on this study, TP53 and PTEN are possibly involved in the pathogenesis of OFC. Further studies on a larger case cohort are needed to further elucidate this mechanism and its effect on clinical behavior of these intriguing tumors.

Entities:  

Keywords:  Hürthle cell carcinoma; Mutation; Next generation sequencing; Oncocytic follicular carcinoma; PTEN; TP53; Thyroid

Mesh:

Substances:

Year:  2015        PMID: 26530486     DOI: 10.1007/s12022-015-9403-6

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  24 in total

1.  Thyroid pathologic findings in patients with Cowden disease.

Authors:  H R Harach; I Soubeyran; A Brown; D Bonneau; M Longy
Journal:  Ann Diagn Pathol       Date:  1999-12       Impact factor: 2.090

2.  Poorly differentiated oxyphilic (Hurthle cell) carcinomas of the thyroid.

Authors:  M Papotti; B Torchio; L Grassi; A Favero; G Bussolati
Journal:  Am J Surg Pathol       Date:  1996-06       Impact factor: 6.394

3.  Poorly differentiated oncocytic (hürthle cell) follicular carcinoma: an institutional experience.

Authors:  Shuting Bai; Zubair W Baloch; Teresa D Samulski; Kathleen T Montone; Virginia A LiVolsi
Journal:  Endocr Pathol       Date:  2015-05       Impact factor: 3.943

4.  Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.

Authors:  Ian Ganly; Julio Ricarte Filho; Stephanie Eng; Ronald Ghossein; Luc G T Morris; Yupu Liang; Nicholas Socci; Kasthuri Kannan; Qianxing Mo; James A Fagin; Timothy A Chan
Journal:  J Clin Endocrinol Metab       Date:  2013-03-29       Impact factor: 5.958

5.  Hurthle cell carcinoma: a population-level analysis of 3311 patients.

Authors:  Paolo Goffredo; Sanziana A Roman; Julie A Sosa
Journal:  Cancer       Date:  2012-08-14       Impact factor: 6.860

6.  Molecular evidence of anaplastic transformation in coexisting well-differentiated and anaplastic carcinomas of the thyroid.

Authors:  Jennifer L Hunt; Michael Tometsko; Virginia A LiVolsi; Patricia Swalsky; Sydney D Finkelstein; E Leon Barnes
Journal:  Am J Surg Pathol       Date:  2003-12       Impact factor: 6.394

7.  RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma.

Authors:  Marina N Nikiforova; Roy A Lynch; Paul W Biddinger; Erik K Alexander; Gerald W Dorn; Giovanni Tallini; Todd G Kroll; Yuri E Nikiforov
Journal:  J Clin Endocrinol Metab       Date:  2003-05       Impact factor: 5.958

Review 8.  Molecular pathogenesis of follicular cell derived thyroid cancers.

Authors:  Rajeev Parameswaran; Susan Brooks; Gregory Paul Sadler
Journal:  Int J Surg       Date:  2010-01-25       Impact factor: 6.071

Review 9.  p53 family proteins in thyroid cancer.

Authors:  R Malaguarnera; V Vella; R Vigneri; F Frasca
Journal:  Endocr Relat Cancer       Date:  2007-03       Impact factor: 5.678

10.  Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers.

Authors:  Zhi Liu; Peng Hou; Meiju Ji; Haixia Guan; Kimberly Studeman; Kirk Jensen; Vasily Vasko; Adel K El-Naggar; Mingzhao Xing
Journal:  J Clin Endocrinol Metab       Date:  2008-05-20       Impact factor: 5.958

View more
  8 in total

1.  Assessment of PTEN-associated vascular malformations in a patient with Bannayan-Riley-Ruvalcaba syndrome.

Authors:  Sandra Anusic; Robert Karl Josef Clemens; Thomas Oleg Meier; Beatrice Ruth Amann-Vesti
Journal:  BMJ Case Rep       Date:  2016-06-29

Review 2.  Clinically Relevant Prognostic Parameters in Differentiated Thyroid Carcinoma.

Authors:  Tyler Janovitz; Justine A Barletta
Journal:  Endocr Pathol       Date:  2018-12       Impact factor: 3.943

3.  Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers.

Authors:  Bryan R Haugen; Daniel W Bowles; Nikita Pozdeyev; Laurie M Gay; Ethan S Sokol; Ryan Hartmaier; Kelsi E Deaver; Stephanie Davis; Jena D French; Pierre Vanden Borre; Daniel V LaBarbera; Aik-Choon Tan; Rebecca E Schweppe; Lauren Fishbein; Jeffrey S Ross
Journal:  Clin Cancer Res       Date:  2018-04-03       Impact factor: 12.531

4.  Widespread Chromosomal Losses and Mitochondrial DNA Alterations as Genetic Drivers in Hürthle Cell Carcinoma.

Authors:  Raj K Gopal; Kirsten Kübler; Sarah E Calvo; Paz Polak; Dimitri Livitz; Daniel Rosebrock; Peter M Sadow; Braidie Campbell; Samuel E Donovan; Salma Amin; Benjamin J Gigliotti; Zenon Grabarek; Julian M Hess; Chip Stewart; Lior Z Braunstein; Peter F Arndt; Scott Mordecai; Angela R Shih; Frances Chaves; Tiannan Zhan; Carrie C Lubitz; Jiwoong Kim; A John Iafrate; Lori Wirth; Sareh Parangi; Ignaty Leshchiner; Gilbert H Daniels; Vamsi K Mootha; Dora Dias-Santagata; Gad Getz; David G McFadden
Journal:  Cancer Cell       Date:  2018-08-13       Impact factor: 31.743

Review 5.  American Head and Neck Society Endocrine Surgery Section and International Thyroid Oncology Group consensus statement on mutational testing in thyroid cancer: Defining advanced thyroid cancer and its targeted treatment.

Authors:  David C Shonka; Alan Ho; Ashish V Chintakuntlawar; Jessica L Geiger; Jong C Park; Nagashree Seetharamu; Sina Jasim; Amr H Abdelhamid Ahmed; Keith C Bible; Marcia S Brose; Maria E Cabanillas; Kirsten Dabekaussen; Louise Davies; Dora Dias-Santagata; James A Fagin; William C Faquin; Ronald A Ghossein; Raj K Gopal; Akira Miyauchi; Yuri E Nikiforov; Matthew D Ringel; Bruce Robinson; Mabel M Ryder; Eric J Sherman; Peter M Sadow; Jennifer J Shin; Brendan C Stack; R Michael Tuttle; Lori J Wirth; Mark E Zafereo; Gregory W Randolph
Journal:  Head Neck       Date:  2022-03-11       Impact factor: 3.821

6.  Thyroid cancer harboring PTEN and TP53 mutations: A peculiar molecular and clinical case report.

Authors:  Carla Colombo; Gabriele Pogliaghi; Delfina Tosi; Marina Muzza; Gaetano Bulfamante; Luca Persani; Laura Fugazzola; Valentina Cirello
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

Review 7.  Multi-omics Signatures and Translational Potential to Improve Thyroid Cancer Patient Outcome.

Authors:  Myriem Boufraqech; Naris Nilubol
Journal:  Cancers (Basel)       Date:  2019-12-10       Impact factor: 6.639

Review 8.  Genetics, Diagnosis, and Management of Hürthle Cell Thyroid Neoplasms.

Authors:  David G McFadden; Peter M Sadow
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-10       Impact factor: 6.055

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.